Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older-Reference-Cited by-同舟云学术

Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older

Published:2020-12-01 Issue:5 Volume:22 Page:543-547
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Gao Jia C.¹^ORCID,Emmerich Veronica K.²,Feldman Steven²³⁴⁵,Strowd Lindsay C.²

Affiliation:

1. New York Medical College, Valhalla, NY, USA

2. Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

3. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

4. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

5. Department of Dermatology, University of Southern Denmark, Odense, Denmark

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1853099

Reference23 articles.

1. Statistics. National Psoriasis Foundation. [cited 2020 Jul 28]. Available from: https://www.psoriasis.org/content/statistics#:~:text=Prevalence,the%20World%20Psoriasis%20Day%20consortium

2. Prevalence of Psoriasis Among Adults in the U.S.

3. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

4. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

5. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures